Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Clinical Features and Treatment Outcomes of Patients With Necrobiotic Xanthogranuloma Associated With Monoclonal Gammopathies.

Higgins LS, Go RS, Dingli D, Kumar SK, Rajkumar SV, Dispenzieri A, Buadi FK, Lacy MQ, Lust JA, Kapoor P, Leung N, Lin Y, Kourelis TV, Gertz MA, Kyle RA, Gonsalves WI.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16(8):447-52. doi: 10.1016/j.clml.2016.04.009. Epub 2016 May 5.

PMID:
27238425
2.

53-Year-Old Man With Fever and Back Pain.

Higgins LS, Tarmey TT, Szostek JH.

Mayo Clin Proc. 2016 Jun;91(6):e75-9. doi: 10.1016/j.mayocp.2015.12.005. Epub 2016 Feb 28. No abstract available.

PMID:
26936320
3.

Monitoring Susceptibility of Western Bean Cutworm (Lepidoptera: Noctuidae) Field Populations to Bacillus thuringiensis Cry1F Protein.

Ostrem JS, Pan Z, Flexner JL, Owens E, Binning R, Higgins LS.

J Econ Entomol. 2016 Apr;109(2):847-53.

PMID:
26748981
4.

Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?

DePaoli AM, Higgins LS, Henry RR, Mantzoros C, Dunn FL; INT131-007 Study Group.

Diabetes Care. 2014 Jul;37(7):1918-23. doi: 10.2337/dc13-2480. Epub 2014 Apr 10.

PMID:
24722496
5.

Assessing the ecological risks from the persistence and spread of feral populations of insect-resistant transgenic maize.

Raybould A, Higgins LS, Horak MJ, Layton RJ, Storer NP, De La Fuente JM, Herman RA.

Transgenic Res. 2012 Jun;21(3):655-64. doi: 10.1007/s11248-011-9560-4. Epub 2011 Oct 15.

6.

Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes.

Dunn FL, Higgins LS, Fredrickson J, DePaoli AM; INT131-004 study group.

J Diabetes Complications. 2011 May-Jun;25(3):151-8. doi: 10.1016/j.jdiacomp.2010.06.006. Epub 2010 Aug 23.

PMID:
20739195
7.

P38alpha-selective mitogen-activated protein kinase inhibitor for improvement of cultured human islet recovery.

Omori K, Todorov I, Shintaku J, Rawson J, Al-Abdullah IH, Higgins LS, Medicherla S, Kandeel F, Mullen Y.

Pancreas. 2010 May;39(4):436-43. doi: 10.1097/MPA.0b013e3181c0dd8f.

8.

Topical alpha-selective p38 MAP kinase inhibition reduces acute skin inflammation in guinea pig.

Medicherla S, Ma JY, Reddy M, Esikova I, Kerr I, Movius F, Higgins LS, Protter AA.

J Inflamm Res. 2010;3:9-16. Epub 2010 Feb 18.

9.

Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation.

Higgins LS, Depaoli AM.

Am J Clin Nutr. 2010 Jan;91(1):267S-272S. doi: 10.3945/ajcn.2009.28449E. Epub 2009 Nov 11. Review.

PMID:
19906796
10.

Three-year field monitoring of Cry1F, event DAS-01507-1, maize hybrids for nontarget arthropod effects.

Higgins LS, Babcock J, Neese P, Layton RJ, Moellenbeck DJ, Storer N.

Environ Entomol. 2009 Feb;38(1):281-92.

PMID:
19791625
11.

p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma.

Medicherla S, Reddy M, Ying J, Navas TA, Li L, Nguyen AN, Kerr I, Hanjarappa N, Protter AA, Higgins LS.

Anticancer Res. 2008 Nov-Dec;28(6A):3827-33.

12.

p38 MAPK inhibition reduces diabetes-induced impairment of wound healing.

Medicherla S, Wadsworth S, Cullen B, Silcock D, Ma JY, Mangadu R, Kerr I, Chakravarty S, Luedtke GL, Dugar S, Protter AA, Higgins LS.

Diabetes Metab Syndr Obes. 2009 Jun 23;2:91-100.

13.

Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment.

Navas T, Zhou L, Estes M, Haghnazari E, Nguyen AN, Mo Y, Pahanish P, Mohindru M, Cao T, Higgins LS, Platanias LC, List A, Verma A, Bhagat T, Gajavelli S, Kambhampati S.

Leuk Lymphoma. 2008 Oct;49(10):1963-75. doi: 10.1080/10428190802322919. Erratum in: Leuk Lymphoma. 2009 Sep;50(9):1554. Bhagat, T [added]; Gajavelli, S [added]; Kambhampati, S [added].

14.

Role of p38 mitogen-activated protein kinase in ozone-induced airway hyperresponsiveness and inflammation.

Williams AS, Issa R, Durham A, Leung SY, Kapoun A, Medicherla S, Higgins LS, Adcock IM, Chung KF.

Eur J Pharmacol. 2008 Dec 14;600(1-3):117-22. doi: 10.1016/j.ejphar.2008.09.031. Epub 2008 Sep 30. Erratum in: Eur J Pharmacol. 2009 May 1;609(1-3):155-6.

PMID:
18926814
15.

The Development of INT131 as a Selective PPARgamma Modulator: Approach to a Safer Insulin Sensitizer.

Higgins LS, Mantzoros CS.

PPAR Res. 2008;2008:936906. doi: 10.1155/2008/936906.

16.

Role of p38 mitogen activated protein kinase in a model of osteosarcoma-induced pain.

Svensson CI, Medicherla S, Malkmus S, Jiang Y, Ma JY, Kerr I, Brainin-Mattos J, Powell HC, Luo ZD, Chakravarty S, Dugar S, Higgins LS, Protter AA, Yaksh TL.

Pharmacol Biochem Behav. 2008 Oct;90(4):664-75. doi: 10.1016/j.pbb.2008.05.016.

PMID:
18584857
17.

Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.

Zhou L, Nguyen AN, Sohal D, Ying Ma J, Pahanish P, Gundabolu K, Hayman J, Chubak A, Mo Y, Bhagat TD, Das B, Kapoun AM, Navas TA, Parmar S, Kambhampati S, Pellagatti A, Braunchweig I, Zhang Y, Wickrema A, Medicherla S, Boultwood J, Platanias LC, Higgins LS, List AF, Bitzer M, Verma A.

Blood. 2008 Oct 15;112(8):3434-43. doi: 10.1182/blood-2008-02-139824. Epub 2008 May 12.

18.

Selection of nontarget arthropod taxa for field research on transgenic insecticidal crops: using empirical data and statistical power.

Prasifka JR, Hellmich RL, Dively GP, Higgins LS, Dixon PM, Duan JJ.

Environ Entomol. 2008 Feb;37(1):1-10.

PMID:
18348790
19.

Pyrimidine-based inhibitors of CaMKIIdelta.

Mavunkel B, Xu YJ, Goyal B, Lim D, Lu Q, Chen Z, Wang DX, Higaki J, Chakraborty I, Liclican A, Sideris S, Laney M, Delling U, Catalano R, Higgins LS, Wang H, Wang J, Feng Y, Dugar S, Levy DE.

Bioorg Med Chem Lett. 2008 Apr 1;18(7):2404-8. doi: 10.1016/j.bmcl.2008.02.056. Epub 2008 Mar 4.

PMID:
18334293
20.

Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment.

Medicherla S, Li L, Ma JY, Kapoun AM, Gaspar NJ, Liu YW, Mangadu R, O'Young G, Protter AA, Schreiner GF, Wong DH, Higgins LS.

Anticancer Res. 2007 Nov-Dec;27(6B):4149-57. Erratum in: Anticancer Res. 2008 Jan-Feb;28(1b):567, 4152-3.

21.

Pharmacological properties of SD-282 - an alpha-isoform selective inhibitor for p38 MAP kinase.

Koppelman B, Webb HK, Medicherla S, Almirez R, Feng Y, Chavez JC, Mao CP, Nguyen A, Liu YW, Kapoun AM, Muiru G, Huang YA, Dugar S, Mavunkel BJ, Lim DW, Chakravarty S, Luedtke G, Protter AA, Higgins LS.

Pharmacology. 2008;81(3):204-20. doi: 10.1159/000112865. Epub 2008 Jan 7.

PMID:
18176091
22.

Selective p38α mitogen-activated protein kinase inhibitor attenuates lung inflammation and fibrosis in IL-13 transgenic mouse model of asthma.

Ma JY, Medicherla S, Kerr I, Mangadu R, Protter AA, Higgins LS.

J Asthma Allergy. 2008 Nov 16;1:31-44.

23.

A p38 mitogen-activated protein kinase inhibitor arrests active alveolar bone loss in a rat periodontitis model.

Rogers JE, Li F, Coatney DD, Otremba J, Kriegl JM, Protter TA, Higgins LS, Medicherla S, Kirkwood KL.

J Periodontol. 2007 Oct;78(10):1992-8.

24.

p38alpha-selective mitogen-activated protein kinase inhibitor SD-282 reduces inflammation in a subchronic model of tobacco smoke-induced airway inflammation.

Medicherla S, Fitzgerald MF, Spicer D, Woodman P, Ma JY, Kapoun AM, Chakravarty S, Dugar S, Protter AA, Higgins LS.

J Pharmacol Exp Ther. 2008 Mar;324(3):921-9. Epub 2007 Dec 4.

PMID:
18056868
25.

Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model.

Tran TT, Uhl M, Ma JY, Janssen L, Sriram V, Aulwurm S, Kerr I, Lam A, Webb HK, Kapoun AM, Kizer DE, McEnroe G, Hart B, Axon J, Murphy A, Chakravarty S, Dugar S, Protter AA, Higgins LS, Wick W, Weller M, Wong DH.

Neuro Oncol. 2007 Jul;9(3):259-70. Epub 2007 May 23. Erratum in: Neuro Oncol. 2007 Oct;9(4):465.

26.

Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.

Vanderkerken K, Medicherla S, Coulton L, De Raeve H, Willems A, Lawson M, Van Camp B, Protter AA, Higgins LS, Menu E, Croucher PI.

Cancer Res. 2007 May 15;67(10):4572-7. Epub 2007 May 10.

27.

Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance.

Small GW, Shi YY, Higgins LS, Orlowski RZ.

Cancer Res. 2007 May 1;67(9):4459-66.

28.

Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.

Gaspar NJ, Li L, Kapoun AM, Medicherla S, Reddy M, Li G, O'Young G, Quon D, Henson M, Damm DL, Muiru GT, Murphy A, Higgins LS, Chakravarty S, Wong DH.

Mol Pharmacol. 2007 Jul;72(1):152-61. Epub 2007 Mar 30.

PMID:
17400764
29.

Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.

Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, Chirgwin JM.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6213s-6216s. Review.

30.

A p38alpha selective mitogen-activated protein kinase inhibitor prevents periodontal bone loss.

Kirkwood KL, Li F, Rogers JE, Otremba J, Coatney DD, Kreider JM, D'Silva NJ, Chakravarty S, Dugar S, Higgins LS, Protter AA, Medicherla S.

J Pharmacol Exp Ther. 2007 Jan;320(1):56-63. Epub 2006 Oct 13.

PMID:
17041006
31.

Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages.

Smith SJ, Fenwick PS, Nicholson AG, Kirschenbaum F, Finney-Hayward TK, Higgins LS, Giembycz MA, Barnes PJ, Donnelly LE.

Br J Pharmacol. 2006 Oct;149(4):393-404. Epub 2006 Sep 4.

32.

Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.

Navas TA, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P, Parmar S, Haghnazari E, Zhou L, Collins R, Kerr I, Nguyen AN, Xu Y, Platanias LC, List AA, Higgins LS, Verma A.

Blood. 2006 Dec 15;108(13):4170-7. Epub 2006 Aug 29.

33.

Disease mechanisms and emerging therapies: protein kinases and their inhibitors in myocardial disease.

Anderson ME, Higgins LS, Schulman H.

Nat Clin Pract Cardiovasc Med. 2006 Aug;3(8):437-45. Review.

PMID:
16874356
34.

Importance of p38 mitogen-activated protein kinase pathway in allergic airway remodelling and bronchial hyperresponsiveness.

Nath P, Leung SY, Williams A, Noble A, Chakravarty SD, Luedtke GR, Medicherla S, Higgins LS, Protter A, Chung KF.

Eur J Pharmacol. 2006 Aug 21;544(1-3):160-7. Epub 2006 Jun 23.

PMID:
16843456
35.

Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses.

Giafis N, Katsoulidis E, Sassano A, Tallman MS, Higgins LS, Nebreda AR, Davis RJ, Platanias LC.

Cancer Res. 2006 Jul 1;66(13):6763-71.

36.

Transforming growth factor-beta receptor type 1 (TGFbetaRI) kinase activity but not p38 activation is required for TGFbetaRI-induced myofibroblast differentiation and profibrotic gene expression.

Kapoun AM, Gaspar NJ, Wang Y, Damm D, Liu YW, O'young G, Quon D, Lam A, Munson K, Tran TT, Ma JY, Murphy A, Dugar S, Chakravarty S, Protter AA, Wen FQ, Liu X, Rennard SI, Higgins LS.

Mol Pharmacol. 2006 Aug;70(2):518-31. Epub 2006 May 17.

PMID:
16707625
37.

Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.

Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I, O'Young G, Kapoun AM, Chakravarty S, Mavunkel B, Perumattam J, Luedtke G, Dugar S, Medicherla S, Protter AA, Schreiner GF, Anderson KC, Higgins LS.

Leukemia. 2006 Jun;20(6):1017-27.

PMID:
16617327
38.

Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.

Nguyen AN, Stebbins EG, Henson M, O'Young G, Choi SJ, Quon D, Damm D, Reddy M, Ma JY, Haghnazari E, Kapoun AM, Medicherla S, Protter A, Schreiner GF, Kurihara N, Anderson J, Roodman GD, Navas TA, Higgins LS.

Exp Cell Res. 2006 Jun 10;312(10):1909-23. Epub 2006 Apr 4.

PMID:
16600214
39.

p38 Inhibition attenuates the pro-inflammatory response to C-reactive protein by human peripheral blood mononuclear cells.

Lim MY, Wang H, Kapoun AM, O'connell M, O'Young G, Brauer HA, Luedtke GR, Chakravarty S, Dugar S, Schreiner GS, Protter AA, Higgins LS.

J Mol Cell Cardiol. 2004 Dec;37(6):1111-4.

PMID:
15572041
40.

Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.

Hayashi T, Hideshima T, Nguyen AN, Munoz O, Podar K, Hamasaki M, Ishitsuka K, Yasui H, Richardson P, Chakravarty S, Murphy A, Chauhan D, Higgins LS, Anderson KC.

Clin Cancer Res. 2004 Nov 15;10(22):7540-6.

41.

SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.

Uhl M, Aulwurm S, Wischhusen J, Weiler M, Ma JY, Almirez R, Mangadu R, Liu YW, Platten M, Herrlinger U, Murphy A, Wong DH, Wick W, Higgins LS, Weller M.

Cancer Res. 2004 Nov 1;64(21):7954-61.

42.

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.

Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT, Hamasaki M, Raje N, Hideshima H, Schreiner G, Nguyen AN, Navas T, Munshi NC, Richardson PG, Higgins LS, Anderson KC.

Oncogene. 2004 Nov 18;23(54):8766-76.

PMID:
15480425
43.

Expression of human apolipoprotein E downregulates amyloid precursor protein-induced ischemic susceptibility.

Koistinaho M, Kettunen MI, Holtzman DM, Kauppinen RA, Higgins LS, Koistinaho J.

Stroke. 2002 Jul;33(7):1905-10.

PMID:
12105373
44.

Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation.

Koistinaho M, Kettunen MI, Goldsteins G, Keinänen R, Salminen A, Ort M, Bures J, Liu D, Kauppinen RA, Higgins LS, Koistinaho J.

Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1610-5. Epub 2002 Jan 29.

45.

Specific spatial learning deficits become severe with age in beta -amyloid precursor protein transgenic mice that harbor diffuse beta -amyloid deposits but do not form plaques.

Koistinaho M, Ort M, Cimadevilla JM, Vondrous R, Cordell B, Koistinaho J, Bures J, Higgins LS.

Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14675-80. Epub 2001 Nov 27.

46.

Insecticidal proteins from Bacillus thuringiensis protect corn from corn rootworms.

Moellenbeck DJ, Peters ML, Bing JW, Rouse JR, Higgins LS, Sims L, Nevshemal T, Marshall L, Ellis RT, Bystrak PG, Lang BA, Stewart JL, Kouba K, Sondag V, Gustafson V, Nour K, Xu D, Swenson J, Zhang J, Czapla T, Schwab G, Jayne S, Stockhoff BA, Narva K, Schnepf HE, Stelman SJ, Poutre C, Koziel M, Duck N.

Nat Biotechnol. 2001 Jul;19(7):668-72.

PMID:
11433280
47.

The nicking endonuclease N.BstNBI is closely related to type IIs restriction endonucleases MlyI and PleI.

Higgins LS, Besnier C, Kong H.

Nucleic Acids Res. 2001 Jun 15;29(12):2492-501.

48.

Tuberculosis and porphyria.

Higgins LS.

Clin Infect Dis. 1999 Sep;29(3):693-4. No abstract available.

PMID:
10530477
49.

Animal models of Alzheimer's disease.

Higgins LS.

Mol Med Today. 1999 Jun;5(6):274-6. No abstract available.

PMID:
10475711
50.

Genetically Engineered Animal Models of Alzheimer's Disease

Higgins LS, Cordell B.

Methods. 1996 Dec;10(3):384-91.

PMID:
8954850

Supplemental Content

Loading ...
Support Center